Home›Screener›LBRX›Profile
C
56/100

LB Pharmaceuticals Inc

LBRXBiotech / Pharma
← Signals View
Analyst Summary
✓ VERIFIED2026-06-17

LB Pharmaceuticals Inc (LBRX) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 3[1], 1 Phase 2[2].

Trial NCT07363577[4] evaluates LB-102 (50 mg tablet) in Schizophrenia with a target enrollment of 456 participants.

Sources

  1. ClinicalTrials.gov (2026-06-17) ↗
  2. ClinicalTrials.gov (2026-06-17) ↗
  3. ClinicalTrials.gov (2026-06-17) ↗
  4. ClinicalTrials.gov · NCT07363577 (2026-05-06) ↗
Clinical Trials
2
NCT07363577Schizophrenia
Source ↗
clinicaltrials_gov · Retrieved 2026-06-17
NCT07494305Bipolar I Disorder
Source ↗
clinicaltrials_gov · Retrieved 2026-06-17
Not financial advice. BiotechSign profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-212026-07-18
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Biotech / Pharma)
GRIGRI Bio, Inc.
A
SUPNSupernus Pharmaceuticals, Inc.
B
EIKNEikon Therapeutics, Inc.
B
CADLCandel Therapeutics, Inc.
B
CMPXCompass Therapeutics, Inc.
B
Data Provenance
clinical trial2 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR